We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Multiple Microbiological Tests Needed for Underweight Newborns

By LabMedica International staff writers
Posted on 03 Mar 2013
Cultures commonly used to detect bacterial infections in low birth-weight newborns with early onset sepsis may fail to detect some microorganisms.

There is a need for multiple detection methods, such as DNA genomic analyses and other independent culture technologies, to identify bacteria that routine culturing may miss.

Scientists at Case Western Reserve University (Cleveland, OH, USA) performed a comparative microbial analysis of paired amniotic fluid (AF) and cord blood (CB) from pregnancies complicated by preterm birth and early-onset neonatal sepsis. More...
The biological samples from 44 women were collected from September 2004 to February 2009.

Amniotic fluid (AF) was cultured for aerobic and anaerobic bacteria, Ureaplasma and Mycoplasma species. DNA was extracted from AF or CB serum. To identify the species amplified by polymerase chain reaction (PCR) and to ensure that the PCR amplicons were indeed bacterial ribosomal ribonucleic acid (rRNA) genes rather than artifacts, the PCR products were cloned into the pCR8 vector (Invitrogen, Carlsbad, CA, USA).

The investigators found more than 20 bacterial species not discovered using standard culturing. Some of the uncultured species appeared in both the cord blood and amniotic fluid samples. The uncultured bacteria were detected with DNA genomic analysis that had been used in a prior study that discovered the link between oral bacteria that causes still- or premature-births due to infected amniotic fluid that is supposed to be a sterile environment.

Yiping Han, PhD, the professor of Periodontics and Reproductive Biology at the Case Western, said, "Culture independent technology has broadened our scope of understanding human pathogens. DNA testing techniques were able for the first time to detect the oral bacteria Fusobacterium nucleatum, Bergeyella, and Sneathia sanguinegens that brought on early neonatal sepsis and put newborns at risk of dying shortly after birth. Among these, F. nucleatum was found at the same high frequency as the well-known Escherichia coli, putting the former on the same importance scale as the latter." The study was published on February 20, 2013, in the journal Public Library of Science ONE.

Related Links:

Case Western Reserve University
Invitrogen



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Portable POCT Blood Gas Analyzer
BD100
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.